-
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
•
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised RMB 200 million (approximately USD 27.8 million) in a Series A+ financing round. The round was led by Youshan Capital, with participation from SIP Oriza Seed Fund, PagodaTree Partners, and Triwise. The company’s pipeline features…
-
Simcere Affiliate Xianbo Biotech Gets China Nod for CAR-T Therapy SNC109
•
Shanghai Xianbo Biotech Co., Ltd, known as Simnova outside of China and an affiliate of Simcere Investment Group, has received tacit clinical trial approval from Chinese authorities for its SNC109, an in-house developed treatment for recurrent glioblastoma. SNC109 is a dual chimeric antigen receptor (CAR)-T cell therapy designed on Xianbo…
